Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers.

Cancer is a genetically individual disease – no two tumors are exactly the same. Genetic changes can create neoantigens – unique targets in or on tumor cells that set them apart from healthy cells. Neogene’s novel approach delivers a tailored therapy based on neoantigen-targeting TCR genes that target neoantigens found in an individual patient’s tumor. Our proprietary TCR identification and selection platform allows us to identify neoantigen-specific TCR genes. These TCR genes are engineered into patient-derived T cells based on in-house developed T cell engineering technologies with the goal of eliciting strong and durable responses in a variety of solid tumor indications. The ability of such engineered T cells to attack a patient tumor can be further modulated through additional, targeted genetic modifications that are explored by Neogene for this purpose.

By developing a portfolio of TCRs targeting common cancer-causing mutations that result in neoantigens shared between patients as well as TCR therapies targeting neoantigens unique to a patient’s tumor, we aim to enable wider access to individualized engineered T cell therapies for a broad spectrum of cancers.